α2-adrenergic

The α2-adrenergic receptor is a family of inhibitory receptors found in the brain and body that respond to norepinephrine and, to a lesser extent, epinephrine. Unlike the closely related α1 receptors, which are broadly excitatory, α2 receptors act as a brake — dampening the very signalling they belong to.

Three subtypes exist — α2A, α2B, and α2C — each with overlapping but distinct distributions. The family belongs to the G protein-coupled receptor superfamily and signals primarily through inhibitory Gi/Go proteins, which lower the activity of downstream enzymes and ion channels.

How it works · its role

α2 receptors do much of their work as autoreceptors: they sit on the same neurons that release norepinephrine, and when those neurons fire, the released norepinephrine loops back and activates them. This tells the neuron to slow down — a classic negative-feedback mechanism that limits how much norepinephrine reaches the synapse.

The same receptors also appear postsynaptically, particularly in the locus coeruleus, the brain's main norepinephrine hub. Activation there quiets arousal pathways, producing sedation, lower blood pressure, and a reduction in the physical signs of stress.

When an α2 agonist such as clonidine or dexmedetomidine binds to these receptors, it mimics the feedback signal, suppressing norepinephrine output across the system. Antagonists such as yohimbine do the opposite — they block the brake, allowing norepinephrine to accumulate.

Relevance to substances & effects

α2 receptors sit at the intersection of several substance classes. Stimulants — amphetamines, cocaine — flood norepinephrine into synapses and overwhelm the autoreceptor brake; the surge of norepinephrine is part of what drives elevated heart rate, alertness, and anxiety at higher doses.

Opioids interact with α2 pathways indirectly. During opioid withdrawal, the locus coeruleus rebounds with excess norepinephrine output, producing the classic withdrawal triad of sweating, rapid heartbeat, and anxiety. Clonidine is used clinically to suppress this rebound by activating α2 receptors and quieting the firing neurons.

The antidepressant mirtazapine works partly as an α2 antagonist: by blocking the autoreceptor brake, it increases the release of both norepinephrine and serotonin. Yohimbine, an extract used in some supplements, acts as an α2 antagonist and reliably elevates anxiety and arousal at higher doses by removing that same brake.

Alcohol and benzodiazepine withdrawal also feature sympathetic hyperactivity, and α2 agonists are sometimes used off-label to manage its physical symptoms — though they address the norepinephrine component, not the underlying GABA rebound.